gnc-035
mAbexperimentalQuad-specific
Clinical trial activity
5 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 8, 2021 (NCT05039931)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
CD3E
- Programmed cell death 1 ligand 1ANTAGONIST
PDL1
ROR1
TNFRSF9 antagonist
Chemistry & pharmacology
- Multi-specific
- Yes (Quad-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06066203 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2023 | Baili Pharmaceutical Group, Peking University |
| NCT05944978 | Phase 1/Phase 2 (Phase 2) | Aug 16, 2023 | Baili Pharmaceutical Group, Chinese Academy of Medical Sciences |
| NCT05104775 | Phase 1 | Nov 30, 2021 | Baili Pharmaceutical Group, Jiao Tong University, SystImmune Inc. |
| NCT05160545 | Phase 1 | Nov 30, 2021 | Baili Pharmaceutical Group, Sun Yat-Sen University |
| NCT05039931 | Phase 1 | Jun 8, 2021 | Baili Pharmaceutical Group, Sichuan University, SystImmune Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baili Pharmaceutical Group | For profit | 5 | 5 | 2 | 2021 |
| SystImmune Inc. | For profit | 2 | 0 | 1 | 2021 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Sichuan University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2021 |
7 organizations
Page 1 / 1